Abstract
Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Minna JD, Higgins GA, Glatstein EJ: In: DeVita VT, Hellman S, Rosenberg SA (eds): Cancer Principles & Practice of Oncology, 2nd ed. Lippincott, Philadelphia, 1985 p 559
Casazza AM, Pratesi G, Giulliani F, DiMarco A: Antileukemic activity of 4 demethoxydaunorubicin in mice. Tumori 66:549–564, 1980
DiMarco A, Zunio F, Casazza AM: Comparison of biochemical and biological methods in evaluation of new anthracycline drugs. Antibiot Chemo 25:12–20, 1978
DiMarco A, Casazza AM, Pratesi G: Antitumor activity of 4-demethoxydaunorubicin orally. Cancer Treat Rep 61:893–894, 1977
Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW: Phase I and clinical pharmacology of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43:6096–6101, 1983
Kaplan S, Sessa C, Willems Y, Pacciarini MA, Tamassia V, Cavalli F: Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses. Invest New Drugs 2:281–286, 1984
Tamassia V, Goldaniga GC, Moro E, Pacciarini MA, Stegnjaich S, Piazza E: Human pharmacokinetic studies on three new anthracyclines. Proceedings of 4th NCI-EORTC Symposium on new drugs in cancer therapy (Abstract). 1983, p 5
Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertlesman R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW: Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (Idarubicin) in adult patients with acute leukemia. Cancer Res 45:1408–1412, 1985
Carella AM Santini G, Martinengo M, Giordano D, Nato S, Congiu A, Cerri R, Risso M, Damasio E, Rossi E, Vimeracati L, Pacciarini MA, Marmont AM: 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemia. Cancer 55:1452–1454, 1985
Bastholt L, Ejlertsen B, Dalmark M: A Phase II trial of oral 4-Demethoxydaunorubicin in patients with measurable advanced carcinoma of the breast (Abstract). Proc. Am Assoc Cancer Res 26:164, 1985
Joss RA, Obrecht JP, Alberto P, Siegenthaler P, Van Helvoirt A, Cavalli F: Phase II trial of 4-Demethoxydaunorubicin in patients with non-small cell lung cancer. Cancer Treat Rep 68:563–564, 1984
Wertheim MS, Kris MG, Gralla RJ, O'Connell JP, Fiore JJ, Kelsen DP, Burke MT, Cibas IR, Heelan RT, Young CW, Kalmon LA: Phase II studies of three new anthracyclines in non-small cell lung cancer (Abstract). Proc Am Soc Clin Onc 4:190, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hochster, H.S., Green, M.D., Blum, R.H. et al. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial. Invest New Drugs 4, 275–278 (1986). https://doi.org/10.1007/BF00179596
Issue Date:
DOI: https://doi.org/10.1007/BF00179596